Major Events - InnoCare Pharma (09926) granted exclusive commercialization rights of Yixineng® to Jichuan Pharmaceutical [1] - Ying Si Intelligent (03696) received a milestone payment of HKD 39 million from Menarini, with the MEN2501 project completing its first patient dosing [1] - Xiansheng Pharmaceutical (02096) received a recent milestone payment related to the overseas licensing option agreement for SIM0500 with AbbVie [1] - Innovent Biologics (02577) completed significant design integration for related products on Google's AI hardware platform and signed a compliant supply agreement [1] - Federal Pharmaceutical (03933) obtained implied approval for clinical trials of UBT251 injection for OSA indications [1] - Kanghong Pharmaceutical (00867) received clinical trial approval for the innovative drug CMS-D017 capsule for complement-mediated kidney disease indications [1] - First Capital Holdings (00697) announced the successful IPO and listing of Shimon Holdings on the Shenzhen Stock Exchange [1] Operating Performance - Country Garden (02007) achieved a contract sales amount of approximately CNY 2.21 billion attributable to shareholders by January 2026 [1] - Nissin Foods (01475) reported an operating profit of JPY 5.672 billion from its China business segment for the first three quarters, representing a year-on-year increase of 99.8% [1] - Natural Beauty (00157) issued a profit warning, expecting an annual net profit of approximately HKD 8 million to HKD 10 million, marking a turnaround from losses [1]

Core Viewpoint - Kangfang Biopharma has signed an exclusive commercialization rights agreement with Jichuan Pharmaceutical, granting Jichuan the exclusive rights to commercialize the drug Yixinning (Inusimab Injection) in mainland China, excluding Hong Kong, Macau, and Taiwan [1][2]. Group 1: Agreement Details - Kangfang Biopharma will receive a total of RMB 80 million (including tax) as an upfront licensing fee from Jichuan Pharmaceutical, along with potential milestone payments not exceeding RMB 10 million (including tax) [1]. - Jichuan Pharmaceutical will be responsible for the commercialization, promotion, and sales of Yixinning in the authorized market [1]. Group 2: Product Information - Yixinning (Inusimab Injection) is a novel PCSK9 monoclonal antibody developed by Kangfang Biopharma, approved for market in September 2024 for treating primary hypercholesterolemia and mixed dyslipidemia, including heterozygous familial hypercholesterolemia (HeFH) [2]. - The drug has been included in the latest National Medical Insurance Directory and is highly recommended in the 2025 edition of expert consensus on managing cardiovascular risks related to blood lipids [2]. - Yixinning works by specifically binding to PCSK9, blocking its interaction with LDL-R, thereby restoring LDL-R expression levels to enhance the clearance of LDL-C from plasma [2].

Group 1 - Jichuan Pharmaceutical has announced the acquisition of exclusive commercialization rights for Kangfang Biotech's PCSK9 monoclonal antibody in mainland China, following a previous announcement regarding a JAK1/JAK2 inhibitor [2] - The company will pay a total of 80 million yuan (including tax) as an authorization fee and up to 10 million yuan (including tax) in milestone payments [4] - The PCSK9 monoclonal antibody, named Inusimab, is designed to specifically bind to PCSK9 and block its interaction with low-density lipoprotein receptors (LDL-R), thereby enhancing the clearance of low-density lipoprotein cholesterol (LDL-C) from the plasma [4] Group 2 - Inusimab is expected to be approved for market launch in September 2024, primarily for the treatment of primary hypercholesterolemia and mixed dyslipidemia, including heterozygous familial hypercholesterolemia (HeFH) and hypercholesterolemia in patients with atherosclerotic cardiovascular disease [4] - The drug will be included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List for 2025, officially implemented from January 1, 2026 [4]

伊喜宁®通过特异性结合PCSK9并阻断其与LDL-R的相互作用，恢复LDL-R的表达水平以提升对血浆中 LDL-C的清除能力。既往研究表明，在他汀类药物背景治疗的基础上接受PCSK9单抗治疗可显著减少人 体的胆固醇水平，降低患者心脏病发作和中风的风险。III期临床研究显示，伊喜宁®对于超高危、极高 危、高危及中低危分层的患者，以及无论LDL-C情况的患者，均具有优异临床疗效，为高胆固醇血症的 临床治疗、心血管风险的长期控制提供了新的选择。 康方生物(09926)公布，公司间接全资附属公司中山康方生物医药有限公司、康融东方(广东)医药有限公 司(以下合称"康方生物")与湖北济川药业股份有限公司全资子公司济川药业集团有限公司、江苏济源医 药有限公司(以下合称"济川药业")于近日签署《独佔性商业化权益协议》，康方生物授权济川药业在合 作期限内，在中华人民共和国(不含中国香港、中国澳门特别行政区和中国台湾地区)拥有公司自主开发 并已获批上市的伊喜宁®(伊努西单抗注射液)的独家商业化权益。本次合作，康方生物将获得由济川药 业支付的人民币8,000万元(含税)授权费，以及最高不超过人民币1,000万元(含税)的里程碑付款 ...

格隆汇2月3日丨康方生物(09926.HK)宣布，公司间接全资附属公司中山康方生物医药有限公司、康融东 方(广东)医药有限公司(以下合称「康方生物」)与湖北济川药业股份有限公司全资子公司济川药业集团 有限公司、江苏济源医药有限公司(以下合称「济川药业」)于近日签署《独占性商业化权益协议》，康 方生物授权济川药业在合作期限内，在中华人民共和国(不含香港、澳门特别行政区和台湾地区)拥有公 司自主开发并已获批上市的伊喜宁?(伊努西单抗注射液)的独家商业化权益。本次合作，康方生物将获 得由济川药业支付的人民币8,000万元(含税)授权费，以及最高不超过人民币1,000万元(含税)的里程碑付 款；济川药业将负责伊喜宁?在授权市场的商业化推广和销售。 ...

伊喜宁®(伊努西单抗注射液)是本公司自主开发创新PCSK9单克隆抗体新药，于2024年9月获批上市，用 于治疗原发型高胆固醇血症和混合型高脂血症，包括杂合子家族性高胆固醇血症(HeFH)及同时患有动 脉粥样硬化性心血管疾病的高胆固醇血症。目前，伊喜宁®已被纳入最新版国家医保目录，并被全面管 理血脂相关心血管风险中国专家共识(2025版)和县域血脂异常合理用药与综合管理指南(2025版)重磅推 荐。 伊喜宁®通过特异性结合PCSK9并阻断其与LDL-R的相互作用，恢复LDL-R的表达水平以提升对血浆中 LDL-C的清除能力。既往研究表明，在他汀类药物背景治疗的基础上接受PCSK9单抗治疗可显著减少人 体的胆固醇水平，降低患者心脏病发作和中风的风险。III期临床研究显示，伊喜宁®对于超高危、极高 危、高危及中低危分层的患者，以及无论LDL-C情况的患者，均具有优异临床疗效，为高胆固醇血症的 临床治疗、心血管风险的长期控制提供了新的选择。 智通财经APP讯，康方生物(09926)公布，公司间接全资附属公司中山康方生物医药有限公司、康融东方 (广东)医药有限公司(以下合称"康方生物")与湖北济川药业股份有限公司全资子 ...

伊喜宁®通过特异性结合PCSK9并阻断其与LDL-R的相互作用，恢复LDL-R的表达水平以提升对血浆中 LDL-C的清除能力。既往研究表明，在他汀类药物背景治疗的基础上接受PCSK9单抗治疗可显著减少人 体的胆固醇水平，降低患者心脏病发作和中风的风险。III期临床研究显示，伊喜宁®对于超高危、极高 危、高危及中低危分层的患者，以及无论LDL-C情况的患者，均具有优异临床疗效，为高胆固醇血症的 临床治疗、心血管风险的长期控制提供了新的选择。 伊喜宁®(伊努西单抗注射液)是本公司自主开发创新PCSK9单克隆抗体新药，于2024年9月获批上市，用 于治疗原发型高胆固醇血症和混合型高脂血症，包括杂合子家族性高胆固醇血症(HeFH)及同时患有动 脉粥样硬化性心血管疾病的高胆固醇血症。目前，伊喜宁®已被纳入最新版国家医保目录，并被全面管 理血脂相关心血管风险中国专家共识(2025版)和县域血脂异常合理用药与综合管理指南(2025版)重磅推 荐。 智通财经APP讯，康方生物(09926)公布，公司间接全资附属公司中山康方生物医药有限公司、康融东方 (广东)医药有限公司(以下合称"康方生物")与湖北济川药业股份有限公司全资子 ...

格隆汇2月3日丨康方生物(09926.HK)宣布，公司间接全资附属公司中山康方生物医药有限公司、康融东 方(广东)医药有限公司(以下合称「康方生物」)与湖北济川药业股份有限公司全资子公司济川药业集团 有限公司、江苏济源医药有限公司(以下合称「济川药业」)于近日签署《独占性商业化权益协议》，康 方生物授权济川药业在合作期限内，在中华人民共和国(不含香港、澳门特别行政区和台湾地区)拥有公 司自主开发并已获批上市的伊喜宁?(伊努西单抗注射液)的独家商业化权益。本次合作，康方生物将获 得由济川药业支付的人民币8,000万元(含税)授权费，以及最高不超过人民币1,000万元(含税)的里程碑付 款；济川药业将负责伊喜宁?在授权市场的商业化推广和销售。 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Akeso, Inc. 康 方 生 物 科 技（ 開 曼 ）有 限 公 司 伊喜寧®通過特異性結合PCSK 9並阻斷其與LDL -R的相互作用，恢復LDL -R的表達 水平以提升對血漿中LDL -C的清除能力。既往研究表明，在他汀類藥物背景治療 的基礎上接受PCSK 9單抗治療可顯著減少人體的膽固醇水平，降低患者心臟病發 作和中風的風險。III期臨床研究顯示，伊喜寧®對於超高危、極高危、高危及中 低危分層的患者，以及無論LDL -C情況的患者，均具有優異臨床療效，為高膽固 醇血症的臨床治療、心血管風險的長期控制提供了新的選擇。 關於康融東方（廣東）醫藥有限公司 （股 份 代 號：9926） 自願公告 康方生物授予濟川藥業伊喜寧®的獨家商業化權益 康方生物科技（ 開曼 ）有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願刊 發，以告知 ...

Group 1 - Kangfang Biotech's AK112 has been proposed for inclusion as a breakthrough therapy for advanced biliary cancer, marking the fifth time it has received such recognition from CDE, offering new hope for patients with poor prognosis [1] - Hengrui Medicine has submitted new indication applications for its drugs, demonstrating the trend of integrating systemic and local treatments in solid tumor therapy, particularly in liver cancer [2] - Innovent Biologics expects a revenue increase of approximately 134% in 2025, projecting around 2.37 billion yuan, with a turnaround to a net profit of about 630 million yuan, driven by sustained commercialization and global business development [3] Group 2 - Roche's 2025 financial report indicates total revenue of approximately 74.37 billion USD, with pharmaceutical business revenue reaching about 57.63 billion USD, reflecting a 9% year-on-year growth [4] - Fosun Pharma has secured commercialization rights for VGX-3100, a therapeutic DNA drug targeting HPV, which is expected to complement existing preventive vaccines and address a significant market for infected individuals [5]